FWBI - First Wave BioPharma Completes Merger Deal With ImmunogenX Adding Phase 3-Ready Candidate For Celiac Disease | Benzinga
First Wave BioPharma Inc (NASDAQ:FWBI) has acquired ImmunogenX in an all-stock transaction with the combined company focused on advancing a gastrointestinal (GI) pipeline.
First Wave BioPharma signed a non-binding term sheet in December to acquire ImmunogenX.
James Sapirstein will continue to serve as Chairman and CEO of First Wave BioPharma, with Dr. Jack Syage, previously the CEO and Co-Founder of ImmunogenX, assuming the role of President and Chief Operating Officer of First Wave BioPharma.
First Wave BioPharma intends to license the commercial rights to latiglutenase in the U.S. and Canada to a global pharmaceutical company.
It will also seek to secure ...